Scheper Verena, Seidel-Effenberg Ira, Lenarz Thomas, Stöver Timo, Paasche Gerrit
Department of Otorhinolaryngology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Hearing4all Cluster of Excellence, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Brain Sci. 2020 Aug 15;10(8):559. doi: 10.3390/brainsci10080559.
Degeneration of neurons, such as the inner ear spiral ganglion neurons (SGN), may be decelerated or even stopped by neurotrophic factor treatment, such as brain-derived neurotrophic factor (BDNF), as well as electrical stimulation (ES). In a clinical setting, drug treatment of the SGN could start directly during implantation of a cochlear implant, whereas electrical stimulation begins days to weeks later. The present study was conducted to determine the effects of consecutive BDNF and ES treatments on SGN density and electrical responsiveness. An electrode drug delivery device was implanted in guinea pigs 3 weeks after deafening and five experimental groups were established: two groups received intracochlear infusion of artificial perilymph (AP) or BDNF; two groups were treated with AP respectively BDNF in addition to ES (AP + ES, BDNF + ES); and one group received BDNF from the day of implantation until day 34 followed by ES (BDNF ⇨ ES). Electrically evoked auditory brainstem responses were recorded. After one month of treatment, the tissue was harvested and the SGN density was assessed. The results show that consecutive treatment with BDNF and ES was as successful as the simultaneous combined treatment in terms of enhanced SGN density compared to the untreated contralateral side but not in regard to the numbers of protected cells.
神经元的退化,比如内耳螺旋神经节神经元(SGN),可能会通过神经营养因子治疗(如脑源性神经营养因子,BDNF)以及电刺激(ES)而减缓甚至停止。在临床环境中,对SGN的药物治疗可在人工耳蜗植入期间直接开始,而电刺激则在数天至数周后开始。本研究旨在确定连续的BDNF和ES治疗对SGN密度和电反应性的影响。在豚鼠致聋3周后植入电极给药装置,并设立五个实验组:两组分别接受人工外淋巴(AP)或BDNF的鼓室内灌注;两组除了ES外,分别接受AP或BDNF治疗(AP + ES,BDNF + ES);一组从植入当天起至第34天接受BDNF治疗,随后接受ES治疗(BDNF ⇨ ES)。记录电诱发听觉脑干反应。治疗一个月后,采集组织并评估SGN密度。结果表明,与未治疗的对侧相比,连续的BDNF和ES治疗在提高SGN密度方面与同时联合治疗同样成功,但在受保护细胞数量方面则不然。